Peer Exchange
The Pharmacy Times® Peer Exchange series is built around video panel discussions featuring some of the most recognizable names in pharmaceuticals. Each program focuses on a specific disease, condition, or therapy, and boasts energetic, moderated conversation on a variety of subjects and questions pertaining to the topic at hand.
What can we help you find?
Implications for using SYK inhibitors as second-line therapy for immune thrombocytopenia over other available treatment options based on current data.
A discussion regarding the increasing frequency of C. difficile recurrence and its effects on patients and the health care system.
Sources of transmission and challenges that impact the management of community-onset C. difficile.
What health care providers need to know about the 2 strains of C. difficile, including types of patients impacted and typical outcomes.
Understanding the burden of C. difficile across the United States, panelists explore common risk factors associated with the condition and discuss the different ways it can manifest in patients.
Recommendations for dosing fostamatinib, a SYK inhibitor, and managing adverse events and drug interactions when utilizing the drug to treat relapsed immune thrombocytopenia.
During a discussion on the adoption of SYK inhibitors as treatment for immune thrombocytopenia, expert panelists remark on the benefits of using the newer oral class of drugs, especially during the COVID-19 pandemic.
The rationale behind the study of SYK inhibitors as treatment for patients with persistent and chronic immune thrombocytopenia who have failed to respond or relapsed after prior therapy.
Considerations when referring to the ASH 2019 guidelines and International Consensus Report for recommendations regarding treatment sequencing to manage immune thrombocytopenia.
Current gaps in data and challenges that impact the treatment of immune thrombocytopenia.
Important considerations regarding the selection of corticosteroids or intravenous immunoglobulin as frontline treatment for immune thrombocytopenia, especially during the COVID-19 pandemic.
Frontline options commonly used to treat immune thrombocytopenia and variables that affect treatment selection.